On Endometrial Cancer
Aghajanian C, Sill MW, Darcy KM, et al: Phase II trial of bevacizumab(Drug information on bevacizumab) in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 29:2259–2265, 2011.
ASTEC/EN.5 Study Group, Blake P, Swart AM, et al: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146, 2009.
Benedetti Panici P, Basile S, Maneschi F, et al: Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 100:1707–1716, 2008.
Hogberg T, Signorelli M, De Oliveira CF, et al: Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomized studies. Eur J Cancer 46:2422–2431, 2010.
Homesley HD, Filiaci V, Gibbons SK, et al: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin(Drug information on cisplatin) and doxorubicin(Drug information on doxorubicin) with or without paclitaxel(Drug information on paclitaxel): A Gynecologic Oncology Group study. Gynecol Oncol 112:543–552, 2009.
Kitchener H, Swart AM, Qian Q, et al: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 373:125–136, 2009.
Kornblith AB, Huang HQ, Walker JL, et al: Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: A Gynecologic Oncology Group study. J Clin Oncol 27:5337–5342, 2009.
McMeekin DS, Filiaci VL, Thigpen JT, et al: The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 106:16–22, 2007.
Miller DS, Fleming G, Randall ME, et al: Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. J Natl Compr Canc Netw 7:535–541, 2009.
Morrow CP, Bundy BN, Kurman RJ et al: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.” Gynecol Oncol 40:55–65, 1991.
Nout RA, Putter H, Jurgenliemk-Schulz IM, et al: Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556, 2009.
Nout RA, Smit VT, Putter H, et al: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 375:816-823, 2010.
Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104, 2009.
Pectasides D, Xiros N, Papaxoinis G, et al: Carboplatin(Drug information on carboplatin) and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109:250–254, 2008.
Susumu N, Sagae S, Udagawa Y, et al: Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233, 2008.
Walker JL, Piedmonte MR, Spirtos NM, et al: Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study. J Clin Oncol 27:5331–5336, 2009.
Walker JL, Piedmonte MR, Spirtos NM et al: Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer. Gynecol Oncol Group LAP2 Study. J Clin Oncol 30:695–700, 2012.
On Gestational Trophoblastic Diseases
Chen LP, Cai SM, Fan JX, Li ZT: PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma. Gynecol Oncol 56:231–234, 1995.
Lurain JR: Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 203:531–539, 2010.
Lurain JR, Schink JC: Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 57:219–224, 2012.
Lurain JR, Singh DK, Schink JC: Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. J Reprod Med 55:199–207, 2010.
Osborne RJ, Filiaci V, Schink JC, et al: Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. J Clin Oncol 29:825–831, 2011.
On Uterine Sarcomas
Hensley ML, Blessing JA, Mannel R, et al: Fixed-dose rate gemcitabine(Drug information on gemcitabine) plus docetaxel(Drug information on docetaxel) as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329–334, 2008.
Kapp DS, Shin JY, Chan JK: Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112:820–830, 2008.
Makker V, Abu-Rustum NR, Alektiar KM, et al: A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol 111:249–254, 2008.
Reed NS, Mangioni C, Malmstrom H, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818, 2008.